* Matritech Inc., of Newton, Mass., received word from the FDA that its NuMA Test Kit for colon cancer does not meet the criteria for 510(k) marketing clearance. Matritech is discussing the ruling with the FDA and also continuing ongoing studies necessary for a premarket approval application, which the company expects to file early next year.
* Nabi, of Boca Raton, Fla., signed an agreement — estimated at about $30 million — with BioProducts Laboratory, a unit of the National Blood Service of England located in Elstree, U.K., to cover shipments of both source and hyperimmune plasma. Nabi will supply plasma at a fixed price during the first year of the contract but has the option to adjust the selling price to reflect market conditions in the second and final year.
* Perkin Elmer Corp., of Norwalk, Conn., and Soane BioSciences Inc., of Hayward, Calif., are collaborating on the development of advanced genetic analysis systems using Soane's microfluidics technology and Perkin-Elmer's genetic analysis technologies. As part of the deal, Perkin-Elmer made an undisclosed equity investment in Soane.
* Therapeutic Antibodies Inc. (TAB), of Nashville, Tenn., and G. D. Searle & Co., the pharmaceutical division of Monsanto Co. of St. Louis, signed an $8 million research collaboration for the identification, development and commercialization of a new antibody based drug. TAB will develop and manufacture a polyclonal antibody for a target indication determined by Searle, which is headquartered in Skokie, Ill. TAB will be responsible for the ongoing supply of product while Searle anticipates holding worldwide marketing rights. Revenues will be shared.